Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash from Financing Activities (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Cash from Financing Activities for 7 consecutive years, with $168.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 202673.49% to $168.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $168.7 million, a 6042.28% increase, with the full-year FY2025 number at $168.7 million, up 6042.28% from a year prior.
  • Cash from Financing Activities was $168.3 million for Q4 2025 at Fulcrum Therapeutics, up from $64000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $168.3 million in Q4 2025 to a low of $64000.0 in Q3 2025.
  • A 5-year average of $31.1 million and a median of $506000.0 in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: crashed 99.68% in 2021, then soared 202673.49% in 2025.
  • Fulcrum Therapeutics' Cash from Financing Activities stood at $891000.0 in 2021, then tumbled by 75.53% to $218000.0 in 2022, then surged by 31.65% to $287000.0 in 2023, then plummeted by 71.08% to $83000.0 in 2024, then skyrocketed by 202673.49% to $168.3 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Cash from Financing Activities are $168.3 million (Q4 2025), $64000.0 (Q3 2025), and $301000.0 (Q2 2025).